- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
DAPA-HF: Dapagliflozin Reduces Incident T2D in Adults with Heart Failure
VIDEO: Silvio Inzucchi, MD, discusses results of a prespecified analysis of the DAPA-HF trial, which found that dapagliflozin reduced new onset diabetes by 32% in patients with heart failure.
In patients with heart failure with reduced ejection fraction (HFrEF), the sodium glucose cotransporter-2 dapagliflozin reduced the incidence of new onset type 2 diabetes (T2D) by 32% vs placebo.
The findings were reported at the 2020 American Diabetes Association Virtual Scientific Sessions by lead investigator Silvio Inzucchi, MD, professor of Medicine, Yale School of Medicine, clinical chief, section of endocrinology, and medical director of the Yale Diabetes Center.
In the video above, Patient Care spoke with Dr Inzucchi about the results of this study, “Effect of dapagliflozin on the incidence of diabetes: a prespecified exploratory analysis from DAPA-HF” and the original DAPA-HF trial and asked for his thoughts on the role of SGLT-2 inhibitors in T2D treatment in primary care.
Please click here for full results of the study.
